Why warfarin can linger in the body
Warfarin reduces the blood’s ability to form clots, but the amount needed varies from person to person. The liver gradually breaks down the drug. The CYP2C9 gene helps determine how quickly it clears one of warfarin’s active forms; some variants make that process slower, so the drug can remain in the body longer.
If warfarin builds up too much, its effect on clotting can become stronger than intended, raising the risk of bleeding. Too little, however, may leave a person vulnerable to clots. Finding the balance is the central challenge of treatment.
What a gene test adds
A test can identify CYP2C9 variants that may slow warfarin breakdown. Clinicians can combine that information with factors such as other medications, diet, health conditions, and the reason for treatment when estimating a suitable dose. Some tests also assess other genes involved in warfarin response.
The result is one piece of the dosing picture, not a dose instruction. Warfarin’s effects are checked with blood tests that measure how long clotting takes, and the dose can be adjusted as those results and a patient’s circumstances change.
Why monitoring still matters
Genes help explain a person’s baseline response, but they cannot capture every influence on warfarin. Changes in medicines, diet, or health can shift its effect even after treatment begins. A gene test can therefore help clinicians anticipate a slower clearance rate, while ongoing blood testing shows how the drug is actually affecting that person.
